Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug677 | CVnCoV 6 μg Wiki | 0.58 |
drug3562 | V-SARS Wiki | 0.58 |
drug676 | CVnCoV 12μg Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.24 |
D018352 | Coronavirus Infections NIH | 0.18 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 3 clinical trials
Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy, at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be collected at baseline and one month later to analyze which type of immune response vaccine has induced.
Description: Routine laboratory complete blood cell count at pre- and post-treatment periods by automated CBC counter Routine laboratory complete blood count Routine clinical laboratory CBC parameters at pre- and post-treatment periods
Measure: Effect on CBC as per CTCAE v4.0 Time: 15 DaysDescription: Routine clinical laboratory blood biochemistry parameters at pre- and post-treatment periods by automated biochemistry analyzer
Measure: Effect on biochemistry parameters as per CTCAE v4.0 Time: 15 DaysDescription: Clinical well-being assessed by CTCAE v4.0
Measure: Lack of adverse events as per CTCAE v4.0 Time: 15 daysThis study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.
Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA). Seroconversion is defined as detectable SARS-CoV-2 RBD of S protein antibodies in the serum of participants who tested seronegative on prior to vaccination on Day 1.
Measure: Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Seroconversion is defined as detectable SARS-CoV-2 N protein antibodies in the serum of subjects on Day 211 and/or Day 393 of the trial, who tested seronegative at prior to vaccination on Day 1 and Day 43.
Measure: Number of Participants Seroconverting to the Nucleocapsid (N) Protein of SARS-SoV-2 Time: Day 1, 43, 211 and 393Description: Measured by a virus neutralizing assay in a subset of participants.
Measure: Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Measured by a virus neutralizing assay in a subset of participants.
Measure: Number of Participants Seroconverting to SARS-CoV-2 Time: Days 1, 29, 43, 57, 120, 211 and 393Description: Measured by a virus neutralizing assay in a subset of participants.
Measure: Individual Serum Antibodies to Spike (S) Protein of SARS-CoV-2 Time: Days 43, 57, 120, 211 and 393This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV.
Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies Time: Day 29Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies Time: Day 43Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum Time: Day 29Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum Time: Day 43Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies Time: Day 29Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies Time: Day 43Description: Measured using an activity assay.
Measure: Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies Time: Day 29Description: Measured using an activity assay.
Measure: Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies Time: Day 43Description: Measured using an activity assay.
Measure: Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum Time: Day 29Description: Measured using an activity assay.
Measure: Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum Time: Day 43Description: Measured using an activity assay.
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies Time: Day 29Description: Measured using an activity assay.
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies Time: Day 43Description: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Number of Participants with Solicited Local Adverse Events Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Duration of Solicited Local Adverse Events Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Number of Participants with Solicited Systemic Adverse Events Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Duration of Solicited Systemic Adverse Events Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine Time: 7 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Number of Participants with Unsolicited Adverse Events Following the Booster Vaccine Time: 28 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine Time: 28 days after booster vaccinationDescription: During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.
Measure: Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine Time: 28 days after booster vaccinationDescription: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies Time: Day 57, Day 85, Day 180, Day 208 and Day 393Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum Time: Day 57, Day 85, Day 180, Day 208 and Day 393Description: Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies Time: Day 57, Day 85, Day 180, Day 208 and Day 393Description: Measured using an activity assay.
Measure: Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies Time: Day 57, Day 85, Day 180, Day 208 and Day 393Description: Measured using an activity assay.
Measure: Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum Time: Day 57, Day 85, Day 180, Day 208 and Day 393Description: Measured using an activity assay.
Measure: Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies Time: Day 57, Day 85, Day 180, Day 208 and Day 393Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports